SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 80.87 |
Enterprise Value ($M) | 68.82 |
Book Value ($M) | 153.68 |
Book Value / Share | 2.58 |
Price / Book | 0.53 |
NCAV ($M) | 107.24 |
NCAV / Share | 1.80 |
Price / NCAV | 0.75 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.33 |
Return on Assets (ROA) | -0.33 |
Return on Equity (ROE) | -0.46 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 7.33 |
Current Ratio | 7.33 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 148.87 |
Assets | 195.31 |
Liabilities | 41.63 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | 0.00 |
Net Income | 0.00 |
Earnings Per Share Basic And Diluted | n/a |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.00 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Ridgeback Capital Investments L.P. | |||
13G/A | Deep Track Capital, LP | |||
13G | BlackRock, Inc. | |||
13D/A | Sullivan Lara | |||
13G | Integrated Core Strategies (us) Llc | |||
13G/A | Laurion Capital Management LP | 6.15 | 14.36 | |
13G/A | Bayer World Investments B.V. | 4.70 | 0.00 | |
13G/A | Tang Capital Partners Lp | 0.00 | -100.00 | |
13G/A | Biotechnology Value Fund L P | 0.00 | -100.00 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
183,010 | 593,711 | 30.82 | |
128,258 | 343,346 | 37.36 | |
118,864 | 400,414 | 29.69 | |
232,089 | 750,432 | 30.93 | |
(click for more detail) |
Similar Companies | |
---|---|
PRLD – Prelude Therapeutics Incorporated | PRTA – Prothena Corporation plc |
PTCT – PTC Therapeutics, Inc. | QDEL – QuidelOrtho Corporation |
QNCX – Quince Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io